• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

JARID1组蛋白去甲基化酶:癌症中新兴的靶点

JARID1 Histone Demethylases: Emerging Targets in Cancer.

作者信息

Harmeyer Kayla M, Facompre Nicole D, Herlyn Meenhard, Basu Devraj

机构信息

Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA 19104, USA.

The Wistar Institute, Philadelphia, PA 19104, USA.

出版信息

Trends Cancer. 2017 Oct;3(10):713-725. doi: 10.1016/j.trecan.2017.08.004. Epub 2017 Sep 12.

DOI:10.1016/j.trecan.2017.08.004
PMID:28958389
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5679451/
Abstract

JARID1 proteins are histone demethylases that both regulate normal cell fates during development and contribute to the epigenetic plasticity that underlies malignant transformation. This H3K4 demethylase family participates in multiple repressive transcriptional complexes at promoters and has broader regulatory effects on chromatin that remain ill-defined. There is growing understanding of the oncogenic and tumor suppressive functions of JARID1 proteins, which are contingent on cell context and the protein isoform. Their contributions to stem cell-like dedifferentiation, tumor aggressiveness, and therapy resistance in cancer have sustained interest in the development of JARID1 inhibitors. Here we review the diverse and context-specific functions of the JARID1 proteins that may impact the utilization of emerging targeted inhibitors of this histone demethylase family in cancer therapy.

摘要

JARID1蛋白是组蛋白去甲基化酶,在发育过程中调节正常细胞命运,并促成恶性转化所依赖的表观遗传可塑性。这个H3K4去甲基化酶家族参与启动子处的多个抑制性转录复合物,对染色质具有更广泛的调节作用,但其作用仍不明确。人们对JARID1蛋白的致癌和抑癌功能的认识不断加深,这些功能取决于细胞背景和蛋白异构体。它们在癌症中对干细胞样去分化、肿瘤侵袭性和治疗抗性的作用,持续引发了对JARID1抑制剂开发的关注。在此,我们综述了JARID1蛋白多样且依赖背景的功能,这些功能可能会影响这种组蛋白去甲基化酶家族新型靶向抑制剂在癌症治疗中的应用。

相似文献

1
JARID1 Histone Demethylases: Emerging Targets in Cancer.JARID1组蛋白去甲基化酶:癌症中新兴的靶点
Trends Cancer. 2017 Oct;3(10):713-725. doi: 10.1016/j.trecan.2017.08.004. Epub 2017 Sep 12.
2
The KDM5 family of histone demethylases as targets in oncology drug discovery.组蛋白去甲基化酶 KDM5 家族作为肿瘤药物发现的靶点。
Epigenomics. 2014 Jun;6(3):277-86. doi: 10.2217/epi.14.14.
3
JARID1/KDM5 demethylases as cancer targets?JARID1/KDM5去甲基化酶可作为癌症治疗靶点吗?
Expert Opin Ther Targets. 2017 Jan;21(1):5-7. doi: 10.1080/14728222.2017.1263616. Epub 2016 Nov 28.
4
Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.组蛋白H3赖氨酸4去甲基化酶KDM5/JARID1家族的一个相连的Jumonji结构域的表征
J Biol Chem. 2016 Feb 5;291(6):2631-46. doi: 10.1074/jbc.M115.698449. Epub 2015 Dec 8.
5
KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges.KDM5 家族作为乳腺癌的治疗靶点:发病机制及治疗机会与挑战。
Mol Cancer. 2024 May 20;23(1):109. doi: 10.1186/s12943-024-02011-0.
6
Jumonji histone demethylases as emerging therapeutic targets.Jumonji 组蛋白去甲基酶作为新兴的治疗靶点。
Pharmacol Res. 2016 Mar;105:146-51. doi: 10.1016/j.phrs.2016.01.026. Epub 2016 Jan 24.
7
Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.赖氨酸去甲基化酶 5B(KDM5B):一种潜在的抗癌药物靶点。
Eur J Med Chem. 2019 Jan 1;161:131-140. doi: 10.1016/j.ejmech.2018.10.040. Epub 2018 Oct 17.
8
Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B.小分子 KDM5 组蛋白去甲基酶抑制剂增加 JARID1B 过表达的乳腺癌细胞的放射敏感性。
Molecules. 2019 May 4;24(9):1739. doi: 10.3390/molecules24091739.
9
KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.KDM5B 是干细胞、发育和癌症中 H3K4 甲基化组的主要调节因子。
Semin Cancer Biol. 2019 Aug;57:79-85. doi: 10.1016/j.semcancer.2018.11.001. Epub 2018 Nov 16.
10
KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.用于抗癌药物的KDM4组蛋白去甲基化酶抑制剂:专利综述
Expert Opin Ther Pat. 2015 Feb;25(2):135-44. doi: 10.1517/13543776.2014.991310. Epub 2014 Dec 3.

引用本文的文献

1
The mTORC2 subunit RICTOR drives breast cancer progression by promoting ganglioside biosynthesis through transcriptional and epigenetic mechanisms.mTORC2亚基RICTOR通过转录和表观遗传机制促进神经节苷脂生物合成,从而推动乳腺癌进展。
PLoS Biol. 2025 Sep 11;23(9):e3003362. doi: 10.1371/journal.pbio.3003362. eCollection 2025 Sep.
2
Decoding Hepatocellular Carcinoma Metastasis: Molecular Mechanisms, Targeted Therapies, and Potential Biomarkers.解读肝细胞癌转移:分子机制、靶向治疗及潜在生物标志物
Curr Issues Mol Biol. 2025 Apr 8;47(4):263. doi: 10.3390/cimb47040263.
3
Nuclear-localized metabolic enzymes: emerging key players in tumor epigenetic regulation.

本文引用的文献

1
H3K4 demethylase KDM5B regulates global dynamics of transcription elongation and alternative splicing in embryonic stem cells.H3K4去甲基化酶KDM5B调节胚胎干细胞中转录延伸和可变剪接的整体动态。
Nucleic Acids Res. 2017 Jun 20;45(11):6427-6441. doi: 10.1093/nar/gkx251.
2
Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma.Y 染色体缺失导致透明细胞肾细胞癌中 KDM5D 和 KDM6C 表观遗传修饰物的下调。
Sci Rep. 2017 Mar 23;7:44876. doi: 10.1038/srep44876.
3
KDM5 lysine demethylases are involved in maintenance of 3'UTR length.
核定位代谢酶:肿瘤表观遗传调控中新兴的关键因子
Mol Cell Biochem. 2025 May 28. doi: 10.1007/s11010-025-05316-w.
4
Zinc and its binding proteins: essential roles and therapeutic potential.锌及其结合蛋白:重要作用与治疗潜力
Arch Toxicol. 2025 Jan;99(1):23-41. doi: 10.1007/s00204-024-03891-3. Epub 2024 Nov 7.
5
Histone demethylase enzymes KDM5A and KDM5B modulate immune response by suppressing transcription of endogenous retroviral elements.组蛋白去甲基化酶KDM5A和KDM5B通过抑制内源性逆转录病毒元件的转录来调节免疫反应。
bioRxiv. 2024 Sep 25:2024.09.23.614494. doi: 10.1101/2024.09.23.614494.
6
Prospects for breast cancer immunotherapy using microRNAs and transposable elements as objects.以微小RNA和转座子为对象的乳腺癌免疫治疗前景。
Explor Target Antitumor Ther. 2024;5(5):1011-1026. doi: 10.37349/etat.2024.00261. Epub 2024 Aug 6.
7
SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma.SETD1B 突变赋予 B 细胞淋巴瘤抗细胞凋亡和 BCL2 独立性。
J Exp Med. 2024 Oct 7;221(10). doi: 10.1084/jem.20231143. Epub 2024 Sep 5.
8
PROTACs Targeting Epigenetic Proteins.靶向表观遗传蛋白的PROTACs
Acta Mater Med. 2023 Oct 26;2(4):409-429. doi: 10.15212/amm-2023-0039. Epub 2023 Dec 6.
9
The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy.组蛋白修饰在肿瘤发生中的作用以及癌症治疗中的相关抑制剂。
J Natl Cancer Cent. 2022 Sep 28;2(4):277-290. doi: 10.1016/j.jncc.2022.09.002. eCollection 2022 Dec.
10
KDM5A/B contribute to HIV-1 latent infection and survival of HIV-1 infected cells.KDM5A/B 有助于 HIV-1 潜伏感染和 HIV-1 感染细胞的存活。
Antiviral Res. 2024 Aug;228:105947. doi: 10.1016/j.antiviral.2024.105947. Epub 2024 Jun 24.
KDM5 赖氨酸去甲基酶参与 3'UTR 长度的维持。
Sci Adv. 2016 Nov 18;2(11):e1501662. doi: 10.1126/sciadv.1501662. eCollection 2016 Nov.
4
Regulation of oncogenic PI3-kinase signaling by JARID1B.JARID1B对致癌性PI3激酶信号传导的调控
Oncotarget. 2017 Jan 31;8(5):7218-7219. doi: 10.18632/oncotarget.14790.
5
Is H3K4me3 instructive for transcription activation?H3K4me3对转录激活具有指导作用吗?
Bioessays. 2017 Jan;39(1):1-12. doi: 10.1002/bies.201600095. Epub 2016 Nov 7.
6
Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias.逃避X染色体失活的肿瘤抑制基因导致癌症的性别差异。
Nat Genet. 2017 Jan;49(1):10-16. doi: 10.1038/ng.3726. Epub 2016 Nov 21.
7
Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition.小鼠卵母细胞中广泛的组蛋白H3K4me3结构域调节母源-合子转变。
Nature. 2016 Sep 22;537(7621):548-552. doi: 10.1038/nature19360. Epub 2016 Sep 14.
8
Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma.JARID1B的过表达通过SHIP1/AKT信号通路促进人下咽鳞状细胞癌的分化。
Cell Death Dis. 2016 Sep 1;7(9):e2358. doi: 10.1038/cddis.2016.262.
9
Hypoxic reprograming of H3K27me3 and H3K4me3 at the INK4A locus.INK4A基因座处H3K27me3和H3K4me3的缺氧重编程。
FEBS Lett. 2016 Oct;590(19):3407-3415. doi: 10.1002/1873-3468.12375. Epub 2016 Sep 7.
10
Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.1,7-萘啶酮作为新型KDM5抑制剂的设计与评价
Bioorg Med Chem Lett. 2016 Sep 15;26(18):4492-4496. doi: 10.1016/j.bmcl.2016.07.070. Epub 2016 Jul 29.